DOH: 1,509 minors with health risks vaccinated vs COVID-19 in first week

Robie de Guzman   •   October 18, 2021   •   237

MANILA, Philippines ­– A total of 1,509 children aged 12 to 17 with co-morbidities were vaccinated in the first week of the pilot implementation of the COVID-19 pediatric vaccination in Metro Manila, the Department of Health (DOH) said Monday.

Health Undersecretary Maria Rosario Vergeire said, the pilot vaccination was successful based on a three-day assessment they conducted.

Vergeire noted that four minors who received the shots reportedly experienced side effects but added that these are still being verified and assessed.

“Isang bata na nagkaroon ng pagtaas ng presyon but after 2 hours they were able to manage it, naging normal na. May nagkaroon ng allergic reaction but it was managed,” she said.

“May dalawang stress-related doon sa immunization, may anxiety sa pagbabakuna. Let me caution all of you, it’s not official yet,” she added.

Vergeire assured they are closely monitoring the condition of minors inoculated with COVID-19 vaccine.

The COVID-19 vaccination for the pediatric population was launched on Oct. 15 in eight hospitals in Metro Manila, namely:

  • Philippine Children’s Medical Center
  • National Children’s Hospital
  • Philippine Heart Center
  • Pasig City General Hospital
  • Fe Del Mundo Medical Center
  • Philippine General Hospital
  • Makati Medical Center
  • Luke’s Medical Center (Taguig)

The following medical conditions would make children aged 12 to 17 years old eligible for vaccination against COVID-19:

  • Medical complexity
  • Genetic conditions
  • Neurologic conditions
  • Cardiovascular disease
  • Metabolic/endocrine
  • Obesity
  • HIV infection
  • Tuberculosis
  • Chronic respiratory disease
  • Renal disorder
  • Hepatobillary

Vergeire earlier said that children participating in the pilot COVID-19 vaccination program should be well-informed and must get clearance from their doctors.

 

PH gov’t tracing 253 passengers from Africa amid looming threat of Omicron

Robie de Guzman   •   December 3, 2021

MANILA, Philippines – The Philippine government is tracing and monitoring more than 200 travelers who arrived in the country from African nations in the last two weeks amid the threat of new COVID-19 variant called Omicron, the Department of Health (DOH) said Friday.

Health Undersecretary Maria Rosario Vergeire said they have traced a total of 253 passengers from South Africa who arrived in the Philippines from November 15 to 29.

“BOQ has started to locate these passengers,” Vergeire said in a virtual press forum.

Of the 253 passengers, 249 were returning overseas Filipinos and four were foreigners. Authorities have traced 71 of these individuals.

The number includes three foreigners still in quarantine in Western Visayas after yielding negative test results.

Vergeire said three of these passengers initially tested positive for COVID-19. One passenger came from South Africa, another from Burkina Faso, and the other from Egypt.

She said samples of these travelers may undergo genome sequencing for variant identification.

“We are still processing the batch that we are going to subject to whole genome sequencing for this week. Results might be tonight or maybe tomorrow,” she said.

“Meron pong dumating na 253 from South Africa noong Nov. 15 to 29, may tatlo galing Burkina Faso; and mayroon 541 galing Egypt. Each of these countries nagkaroon ng isang traveler who tested positive for COVID-19,” she added.

The Philippine government banned the entry of travelers – except for Filipino repatriates – from South Africa, Botswana, Namibia, Zimbabwe, Lesotho, Eswatini, and Mozambique, Austria, the Czech Republic, Hungary, the Netherlands, Switzerland, Belgium, and Italy until December 15 as a precautionary measure against the Omicron variant.

The DOH said the heavily mutated variant and potentially more infectious than other coronavirus variants have now been detected in 35 countries.

The variant was first discovered in South Africa.

It has been designated as a variant of concern but the World Health Organization said further studies are needed to better understand the variant’s effect on vaccines, treatment, and the virus’ transmissibility.

24K expired AstraZeneca vaccine doses sa Western Visayas, susuriin kung maaari pang gamitin – DOH

Robie de Guzman   •   December 3, 2021

Ipinapasuri na ng Department of Health (DOH)-Western Visayas kung maaari pang gamitin ang nasa 24,000 doses ng AstraZeneca COVID-19 vaccine na nag-expire noong November 30.

Bahagi ito ng libu-libong supply ng AstraZeneca vaccine na ipinadala sa Western Visayas noong buwan ng Oktubre.

Nasa 45,000 doses sa mga ito ang ipinadala sa Negros Occidental noong Nobyembre 8. Batay sa ulat ng provincial government, 14,920 doses pa ang natitira sa mga ito at hindi nagamit hanggang sa mag-expire noong Nobyembre 30.

Ayon kay Negros Occidental provincial administrator Atty. Rayfrando Diaz II, hindi ginamit ang mga nasabing bakuna dahil tumanggi umano ang mga local government unit (LGU) na tanggapin ito dahil sa nalalapit na expiration date.

“We value our vaccines. We want to use them. We do not delay, but we value more the vaccinees. We don’t want to inject vaccines that are about to expire,” ani Diaz.

Ang natitirang 10,000 doses naman ay nasa iba’t ibang lokalidad.

Ayon sa DOH regional office, ipinasasauli na nila ang mga nasabing bakuna upang masuri kung maaari pa itong gamitin.

Ayon kay Bea Camille Natalaray, ang tagapagsalita ng DOH Region 6, hihingan rin ng paliwanag ang concerned LGUs kung bakit hindi nagamit ang nasabing supply.

“Magpapasa sila ng incident report to explain bakit hindi nila na-utilize ang vaccine within the period of time. Ano ang mga factors konoconsider para next time maging part na siya ng ating mga guidelines or protocols or strategies,” ani Natalaray.

Sa ngayon ay hinihintay pa ng DOH-6 ang magiging desisyon ng central office kung dapat bang managot ang mga LGU sa pagkasira ng mga bakuna. (mula sa ulat ni Correspondent Lalaine Moreno)

Pharma companies to develop drugs based on COVID-19 variant

Maris Federez   •   December 3, 2021

MANILA, Philippines — Pharmaceutical companies are looking into developing drugs specific to each COVID-19 variant.

Health experts involved in the clinical trial of molnupiravir in the country said the oral anti-viral pill can help  fight the Omicron variant.

The Philippine Food and Drug Administration (FDA), however, stressed the need for extensive studies to check on the efficacy of the anti-viral pill against COVID-19.

Based on data collected in the previous clinical trial results, molnupiravir is able to prevent the condition of patients with mild or moderate COVID-19 symptoms from getting worse.

The Philippines is one of the countries that participated in the global clinical trial of molnupiravir.

According to medical experts and clinical investigators in the country, molnupiravir can help destroy COVID-19 variants of concern like the heavily mutated Omicron.

“The game changer of this pandemic or any other pandemic or any other disease in the world will always be the treatment. Kasi kapag may gamot, mas madaling i-address iyong problemang iyon,” said Dr. Benjamin Co, clinical investigator from the Asian Hospital Medical Center.

“You’re able to diagnose patients early, you are able to treat them even if they are breakthrough infections, and you are able to see patients who are exposed to those index cases,” he added.

“The mutant strains would still respond kasi doon sa core or inner mechanism nagwo-work iyong molnupiravir and not sa surface or sa superficial na spike proteins niya,” said Dr. Joel Santiaguel, clinical investigator from the Quirino Memorial Medical Center.

“Kahit magka-variation na mutation, may changes doon sa spike protein. Active pa rin ang molnupirvir mo against the virus,” he added.

The FDA also said that even the investigational drugs against COVID-19 that are currently being used are able to give relief to patients.

Nevertheless, the FDA underscored the need for in-depth studies to prove the efficacy of the new anti-COVID-19 drugs.

“Iyong mga gamot for severe COVID katulad ng mga steroid, katulad ng tocilizumab, baricitinib kapag severe case, aandar pa rin iyan sa dito sa Omicron,” FDA director-general Usec. Eric Domingo said.

“Pero hindi pa natin sigurado ang ibang gamot, itong monoclonal antibodies at mga antiviral, iyong mga bago kung magwo- work sila, as well,” the FDA chief added.

Clinical investigators invite volunteers for the one-month Phase-3 of the clinical trial for molnupiravir in the Philippines.

They must be 18 years old or older, unvaccinated, and with exposure to a COVID-19 positive person or to an Index Case.

Index cases are mostly economic or medical frontliners who expose family members when they go home.

The clinical trials will check the efficacy of molnupiravir against the Omicron variant.

Blood specimens will be collected from the participants to check the variant that an individual possesses and the effect of molnupiravir on them.

“Genotyping is very important so that we know what the variant of the individual is. Remember when this clinical trial was rolled out, the variants of concern were already rolling out in the world – si Gamma, si Beta, si Alpha, si Delta,” Dr. Co said.

“And that’s the reason why you can see how successful this drug is in addressing the concern of whether it will work or it will not work with SARS- COV2 infection. So far, ang datos po shows that it is very good drug,” he added. —/mbmf (from the report of UNTV Correspondent Aiko Miguel)

REACH US

The Philippine Broadcast Hub

UNTV, 915 Barangay Philam,

EDSA, Quezon City M.M. 1104

(+632) 8396-8688 (Tel)

info@untv-newsandrescue.com (General inquiries)

ABOUT UNTV

UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.